Comparative study between Tokisyakuyakusan and mecobalamin for the efficacy in patients with olfactory dysfunction post-respiratory infection.

Comparative study between Tokisyakuyakusan and mecobalamin for the efficacy in patients with olfactory dysfunction post-respiratory infection. - Comparative study between Tokisyakuyakusan and mecobalamin for the efficacy in patients with olfactory dysfunction post-respiratory infection.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021006

Enrollment

100

Registered

2016-02-13

Start date

2016-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

olfactory dysfunction

Interventions

Tokisyakuyakusan 7.5g/day 3 times a day, before meals 24 weeks Mecobalamin 1500&amp

micro

g/day 3 times a day, after meals 24 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with olfactory dysfunction post-respiratory infection who have developed from at least four weeks ago and within less than one year. 2) Patients aged 20 years old or more and 60 years old or less. 3) Gender unquestioned 4) Outpatient 5) Patients with olfactory dysfunction who have odor recognition thresholds by T&T olfactometry as 2.6 and more (moderate or severe dysosmia) 6) Patients who have given voluntary written informed consent.

Exclusion criteria

Exclusion criteria: 1) Patients who have rhinosinusitis which is subjected to effect on olfactory dysfunction post-respiratory infection. 2) Patients who used Tokisyakuyakusan or mecobalamin within the last two weeks (It will be eligible if they do not use those medicine for at least two weeks). 3) Patients who are pregnant, suspected to be pregnant or breastfeeding. 4) Patients who desire to bear children 5) Patients who are considered not to be eligible by the investigator.

Design outcomes

Primary

Measure	Time frame
Evaluation with T&T olfactometry after the treatment for 24 weeks.	—

Countries

Japan

Contacts

Public ContactHideaki Shiga

Kanazawa Medical University Otorhinoaryngorogy

shigah@kanazawa-med.ac.jp076-286-2211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026